31 Oct, EOD - Indian

SENSEX 79389.06 (-0.69)

Nifty 50 24205.35 (-0.56)

Nifty Bank 51475.35 (-0.64)

Nifty IT 40407.55 (-3.03)

Nifty Midcap 100 56112.85 (-0.40)

Nifty Next 50 69911.75 (-0.51)

Nifty Pharma 22735.55 (1.61)

Nifty Smallcap 100 18602.6 (1.15)

31 Oct, EOD - Global

NIKKEI 225 38053.67 (-2.63)

HANG SENG 20506.44 (0.93)

S&P 5763.25 (0.22)

Login/Signup
LOGIN HERE
Cancel

Dr Lal Pathlabs Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 539524 | NSE Symbol : LALPATHLAB | ISIN : INE600L01024 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
16-Oct-2024 23-Oct-2024 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended 30-09-2024 and to consider the proposal of declaration of 2nd Interim Dividend if any on the Equity Shares of the Company for the Financial Year 2024-25. Attached (As Per BSE Announcement Dated on 23.10.2024)
13-Aug-2024 13-Aug-2024 Employee Stock Option Outcome of Board Meeting dated Aug 13, 2024
31-Jul-2024 07-Aug-2024 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30 2024 and to consider recommending Interim Dividend if any on the Equity Shares of the Company for the Financial Year 2024-25. Outcome of Board Meeting held on August 7, 2024 Declaration of Interim Dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year 2024-25. The record date for the purpose of payment of Interim Dividend shall be August 20, 2024. The Interim Dividend will be dispatched/ credited within 30 days of its declaration. Results for quarter ended June 30, 2024 (As Per BSE Announcement Dated on 07.08.2024)
03-May-2024 10-May-2024 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial year ended March 31 2024 and to consider recommending Final Dividend if any Outcome of Board Meeting (As Per BSE Announcement Dated on 10.05.2024)
17-Mar-2024 17-Mar-2024 Change in Other Executives Based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held today i.e., March 17, 2024, inter-alia, approved the re-designation of Mr. Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024
25-Jan-2024 01-Feb-2024 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2024 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the Quarter and Nine Months ended December 31 2023 and declaration of 2nd interim dividend if any on the equity shares of the Company for the Financial Year 2023-24. Board of Directors in their meeting held today i.e. February 01, 2024, inter-alia, considered and approved the following: i. Un-Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter & Nine Months ended December 31, 2023. ii. Payment of 2nd Interim Dividend of INR 12/- per equity share (@ 120% on a face value of INR 10/- per share) for the FY 2023-24. The record date for the purpose of payment of 2nd Interim Dividend shall be February 13, 2024. Financial Results for the quarter and nine months ended December 31, 2023 Outcome of Board Meeting held on February 01, 2024 Board of Directors in their meeting held on February 01, 2024 inter-alia approved payment of 2nd Interim Dividend for FY 2023-24 Board of Directors in their meeting held on February 01, 2024 approved payment of 2nd Interim Dividend for FY 2023-24 (As Per BSE Announcement Dated on 01.02.2024)
25-Oct-2023 02-Nov-2023 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 inter alia to consider and approve unaudited (standalone and consolidated) financial results for the Quarter and Half Year ended September 30 2023. Financial Results for the Quarter and Half Year ended September 30, 2023 Outcome of Board Meeting for approval of Financial Results for the Quarter and Half Year ended September 30, 2023 (As Per BSE Announcement dated on 02.11.2023)
20-Jul-2023 27-Jul-2023 Accounts Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday July 27 2023 to inter-alia consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30 2023 and to consider the proposal of declaration of interim dividend if any on the equity shares of the Company for the Financial Year 2023-24. Un-Audited Financial Results for the quarter ended June 30, 2023 Board of Directors in their meeting on July 27, 2023 approved payment of Interim Dividend INR 6/- per equity shares for FY 2023-24 Board Meeting Outcome of Board Meeting Held on July 27, 2023 Board of Directors in their meeting held on July 27, 2023, approved appointment of Mr. Gurinder Singh Kalra and Mr. Rajit Mehta as Independent Directors Board of Directors in their meeting held on July 27, 2023 approved granting of ESOPs to eligible employees (As per BSE Announcement Dated on 27/07/2023)
03-May-2023 11-May-2023 Accounts Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 inter alia to consider and approve Audited (Standalone & Consolidated) Financial Results for the period ended March 31 2023 and to consider recommending Final Dividend if any Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia considered and approved the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023. Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia approved the following(s): 1. Recommendation of final dividend of Rs. 6/- per equity share (@ 60% on a face value of Rs. 10/- per share) for the year ended March 31, 2023 subject to approval of the Shareholders at the forthcoming Annual General Meeting ('AGM') of the Company. Information regarding record date for payment of final dividend, if any, will be intimated in due course; 2. Appointment of Mr. Vinay Gujral as Company Secretary (KMP) of the Company w.e.f. May 11, 2023; 3. Appointment of M/s Ernst & Young LLP (EY) as the Internal Auditors of the Company for the Financial Year 2023-24; 4. Appointment of M/s A.G. Agarwal & Associates as the Cost Auditors of the Company for the Financial Year 2023-24; Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia recommended final dividend of Rs. 6/- per equity share (@ 60% on a face value of Rs. 10/- per share) for the year ended March 31, 2023 subject to approval of the Shareholders at the forthcoming Annual General Meeting ('AGM') of the Company. Information regarding record date for payment of final dividend, if any, will be intimated in due course. Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia approved the Appointment of Mr. Vinay Gujral as Company Secretary (KMP) of the Company w.e.f. May 11, 2023; (As Per BSE Announcement Dated on 11/05/2023)
12-Apr-2023 12-Apr-2023 Employee Stock Option We wish to inform you that, the Board of Directors have on April 12, 2023 approved allotment of 16,000 Equity Shares under the ESOP 2010 Plan of the Company.
24-Jan-2023 02-Feb-2023 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ended December 31 2022. Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process. The Board Meeting commenced at 11:00 A.M and concluded at 02:00 P.M. Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process. Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Arun Duggal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority. Disclosure as required under Regulation 30 of the Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as an Annexure- B. The Board Meeting commenced at 11:00 A.M and concluded at 02:00 P.M. (As Per BSE Announcement Dated on 02.02.2023)
01-Nov-2022 08-Nov-2022 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30 2022. Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Half Year ended September 30, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from November 08, 2022 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority. (As Per BSE Announcement Dated on 08.11.2022) Pursuant to the Regulation 30 of the SEBI Listing Regulations, please find attached copies of newspaper advertisement of Financial Results of the Company for the quarter and half year ended on September 30, 2022, published in Financial Express and Jansatta on November 09, 2022. (As Per BSE Announcement Dated on 09/11/2022)
20-Jul-2022 28-Jul-2022 Quarterly Results Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30 2022 and to consider the proposal of declaration of interim dividend if any on the Equity Shares of the Company for the Financial Year 2022-23. Please take note that the Board of Directors in their meeting held today i.e. July 28, 2022 approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended June 30, 2022. A copy of the Results along with Limited Review Report issued by the Statutory Auditors M/s Deloitte Haskins & Sells, LLP on such financials for the first quarter ended June 30, 2022 is attached herewith. At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 6/-per equity share (i.e. 60% on a face value of Rs. 10/- per share) for the FY 2022- 23. The Board Meeting commenced at 11.00 A.M. and the item related to the Financial Results for the first quarter ended June 30, 2022 was approved by the Board at 1:00 P.M. The Board Meeting is still continuing for discussing other Agenda Item(s). We request you to please take the same on record. (As Per BSE Announcement Dated on 28.07.2022)
06-May-2022 17-May-2022 Accounts Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2022 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31 2022 and to consider recommending Final Dividend if any on the Equity Shares of the Company for the Financial Year ended March 31 2022. We request you to kindly take the same on record. Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 Recommendation of final dividend of Rs.6/- per equity share (@ 60% on a face value of Rs.10/- per share) for the year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) will be dispatched/ credited within 30 days of the AGM. Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved following matters: 1. The Audited Standalone and Consolidated Financial Results ('Results') of the Company for the Quarter and Financial Year ended March 31, 2022. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith as Annexure-A. Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved, the re-appointment of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration No. 117366W/W - 100018) as the Statutory Auditors of the Company for a period of five years commencing from the conclusion of 28th Annual General Meeting (AGM) till the conclusion of the 33rd AGM of the Company, subject to the approval of the shareholders at the ensuing 28th AGM of the Company. Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the disclosure as required is enclosed herewith as Annexure B. Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved Dr. Lal PathLabs Employees Stock Option Plan 2022, subject to the approval of Shareholders in ensuing Annual General Meeting of the Company. (As Per BSE Announcement Dated on 17.05.2022)
06-May-2022 06-May-2022 Employee Stock Option We wish to inform you that, the Board of Directors have on May 06, 2022 approved allotment of 7,000 Equity Shares under the ESOP 2010 Plan of the Company. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company stand increased from INR 83,34,48,770/- divided into 8,33,44,877 Equity Shares of INR 10 /- each to INR 83,35,18,770/- divided into 8,33,51,877 Equity Shares of INR 10/- each. We request you to kindly take the above information on record.
1 2